Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-111 first-in-human safety, pharmacokinetics, food effect, formulation, and drug-drug interaction study
NL-OMON53911Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of JMKX000623 in chronic pain and Neuralgia (5 arms), sponsored by Orion Corporation. Started Sep 2022; status: completed.
02
Drugs
JMKX000623
03
Conditions
chronic painNeuralgia
Beyond the preview
Go deeper on NL-OMON53911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53911.